Inhibikase Therapeutics's total assets for Q3 2025 were $79.59M, a decrease of -10.42% from the previous quarter. IKT total liabilities were $6.70M for the fiscal quarter, a -23.90% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.